News for AstraZeneca PLC (AZN)

Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly rolled back -- or at least paused -- these plans. Let's consider two such corporations: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS).

\nRegulatory News:\n\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (â\u0080\u009cInnateâ\u0080\u009d or the â\u0080\u009cCompanyâ\u0080\u009d) today announced it will propose to its Annual Genera

The major U.S. index futures are currently pointing to a lower open on Tuesday, with stocks likely to give back ground after moving notably higher over the two previous sessions.

Focus on oncology, cardiovascular, and respiratory therapeutic areas.Strong pipeline with multiple late-stage clinical trials.Risks include regulatory challeng

We recently published a list of 10 Best UK Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best UK stocks to invest in. Like most of the world, the United Kingdom is also facing slower economic growth in 2025, […]

Shares of AstraZeneca PLC (AZN) fell 4.47% in mid-day trading on Apr 9. The stock reached an intraday low of $61.24, before recovering slightly to $62.00, d

U.S. markets staged a remarkable comeback on Wednesday, April 9, 2025, as investors appeared to find their footing after one of the most volatile trading

AstraZeneca's (AZN) shares decline 4.9% amid looming U.S. tariffs on pharmaceutical imports. Analysts forecast a strong price target, suggesting signifi

Les droits de douane de 104 % que Trump menaçait d'imposer à la Chine sont entrés en vigueur et des droits de douane

The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U.S. imposed wide-ranging tariffs overnight and China responded with higher tariffs on U.S. goods.

Might the tariff risk for pharmaceutical stocks be less than you think?

The S&P 500 futures dropped 87 points, a change of 1.8%. Nasdaq 100 futures fell by 255 points, showing a 1.5% decline. Dow Jones Industrial Average futures are

Key Highlights: AstraZeneca (AZN) shows substantial growth prospects with strategic acquisitions, targeting $80 billion in sales by 2030. Analysts predic

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.

AstraZeneca (AZN) shares increased by 8% last quarter, bolstered by key EU drug approvals. Analysts forecast a potential upside of 34.49% with an averag

AstraZeneca's Imfinzi receives EU approval for NSCLC treatment with chemotherapy. Analysts predict a potential 34.49% upside for AstraZeneca stock. C

AstraZeneca and Daiichi Sankyo secure EU approval for Enhertu, expanding treatment options for breast cancer patients. Analysts forecast significant ups

AstraZeneca's SERENA-6 Phase III trial shows promising results for camizestrant in breast cancer treatment. Analysts forecast a significant potential up

Key Takeaways: AstraZeneca (AZN) is forecasted to have a potential upside of over 33% based on current analyst price targets and GF Value estimates. The